Assessments
PD‐L1, tumor, Tumor, Cancer
ADVERSE EVENT, TUMOR, TUMOR, ADVERSE EVENT, CPS, CANCER
Tumor imaging was performed at baseline, at weeks 8, 16, and 24 from randomization, then every 9 weeks for the first year and every 12 weeks thereafter. Responses were assessed by RECIST version 1.1 by blinded independent central review. Survival was assessed every 12 weeks until withdrawal of consent or end of study. Adverse events (AEs) were monitored from the time of randomization through 30 days following cessation of treatment (90 days for serious AEs) and were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Baseline tumor PD‐L1 expression was assessed using PD‐L1 IHC 22C3 pharmDx (Agilent Technologies) at a central laboratory and reported as CPS, defined as the number of PD‐L1‐positive tumor cells, lymphocytes, and macrophages divided by the total number of tumor cells multiplied by 100.